Management of bleeding emergencies: When to use recombinant activated Factor VII

Research output: Contribution to journalReview articlepeer-review

5 Scopus citations


Recombinant activated Factor VII (rVIIa) was originally released as a clotting factor, with use limited to a select group of patients who had few other treatment options. Due to the apparent ability of rVIIa to stop bleeding, no matter what the underlying cause, there is great interest in use of rVIIa in a wide range of bleeding patients. This article discusses rVIIa and its uses in a variety of patients, especially liver disease and trauma patients, and makes suggestions for appropriate use. Although most of the reports on rVIIa are anecdotes and case series, there is increasing data for clinical trials to help guide usage.

Original languageEnglish (US)
Pages (from-to)25-34
Number of pages10
JournalExpert Opinion on Pharmacotherapy
Issue number1
StatePublished - Jan 2006


  • Bleeding emergencies
  • Haemorrhage
  • Recombinant activated Factor VII
  • Transfusion

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)


Dive into the research topics of 'Management of bleeding emergencies: When to use recombinant activated Factor VII'. Together they form a unique fingerprint.

Cite this